These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

642 related items for PubMed ID: 11067732

  • 21. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M.
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract] [Full Text] [Related]

  • 22. US lawmakers tackle safety reforms at the FDA.
    Zwillich T.
    Lancet; 2007 Jun 16; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract] [Full Text] [Related]

  • 23. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL.
    J Natl Cancer Inst; 2005 Jun 15; 97(12):872-3. PubMed ID: 15956645
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK.
    Food Drug Law J; 2006 Jun 15; 61(3):577-83. PubMed ID: 16989041
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The Food and Drug Administration's requirements for approval of new dental drugs.
    Gilkes CC.
    Symp Pharmacol Ther Toxicol Group; 1975 Apr 06; ():5-12. PubMed ID: 1064180
    [No Abstract] [Full Text] [Related]

  • 28. Ensuring the safety of genotech drugs through implied warranty theory.
    Serra WM.
    Am J Law Med; 1997 Apr 06; 23(2-3):363-81. PubMed ID: 9262761
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. "Safer, but not safe enough".
    Crombie HD.
    Conn Med; 2006 Apr 06; 70(10):645. PubMed ID: 17190395
    [No Abstract] [Full Text] [Related]

  • 31. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
    Murphy S, Roberts R.
    J Allergy Clin Immunol; 2006 Jan 06; 117(1):34-9. PubMed ID: 16387581
    [Abstract] [Full Text] [Related]

  • 32. Health care policy. Reforming off-label promotion to enhance orphan disease treatment.
    Liang BA, Mackey T.
    Science; 2010 Jan 15; 327(5963):273-4. PubMed ID: 20075234
    [No Abstract] [Full Text] [Related]

  • 33. Rare diseases, orphan drugs, and orphaned patients.
    Scheindlin S.
    Mol Interv; 2006 Aug 15; 6(4):186-91. PubMed ID: 16960139
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK, Swartz L.
    Arch Intern Med; 2005 Jun 27; 165(12):1363-9. PubMed ID: 15983284
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.